An Observational Study of Avastin (Bevacizumab) in Patients With Glioblastoma Multiforme in First or Second Relapse

A Single-arm, Open-label, Multicenter, Non-interventional Study to Assess Bevacizumab (Avastin) in Relapsed Glioblastoma

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01618747

Enrollment

Registered

2012-06-13

Start date

2013-03-15

Completion date

2015-12-24

Last updated

2018-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Glioblastoma Multiforme

Brief summary

This single-arm, open-label, multicenter, observational study will evaluate the efficacy and safety of Avastin (bevacizumab) in patients with glioblastoma multiforme in first or second relapse. Data will be collected from eligible patients initiated on Avastin treatment according to local label for up to 3 years.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Adults patients, \>/= 18 years of age * Histologically confirmed glioblastoma multiforme in first or second relapse

Exclusion criteria

* Patients not qualifying for Avastin treatment as per local label

Design outcomes

Primary

Measure	Time frame
Progression-free survival at 6 months	approximately 3 years

Secondary

Measure	Time frame
Progression-free survival	approximately 3 years
Time to disease progression	approximately 3 years
Duration of objective response	approximately 3 years
Overall survival	approximately 3 years
Safety: Incidence of adverse events	approximately 3 years

Countries

Taiwan

Outcome results